NRM Corporation Pty Ltd v Australian Competition and Consumer Commission

The case of NRM Corporation Pty Ltd v Australian Competition and Consumer Commission involved a dispute over unfair contract terms and unconscionability under Australian consumer protection law. The respondents, NRM Corporation Pty Ltd and AMI Corporation Pty Ltd, appealed against findings made by the primary Judge in a decision that their business practices were unconscionable and that certain contract terms were unfair. The primary issues for the court were whether the primary Judge made findings outside the scope of the pleadings, whether there was an absence of clinical evidence as to the efficacy of the medications offered, and whether the findings regarding the remuneration of salespeople and the use of high-pressure sales techniques were supported by the evidence. The court had to consider whether the primary Judge erred in making certain findings of fact and if those findings led to a correct conclusion on the issue of unconscionability.

The court found that the primary Judge did not err in making findings outside the scope of the pleadings as the issues canvassed at the hearing were sufficiently broad to encompass the matters decided by the primary Judge. It was also determined that the primary Judge's findings regarding the lack of clinical evidence supporting the efficacy of the medications were supported by the evidence presented. The court emphasised the importance of viewing the findings in their full context rather than in isolation. Regarding the remuneration of salespeople and the use of high-pressure sales techniques, the court held that the findings were adequately supported by the evidence and were integral to the primary Judge's reasoning on unconscionability. The court was satisfied that the primary Judge's conclusions were properly drawn from the evidence and that there was no error in the findings that led to the ultimate conclusion of unconscionability.

The appeal was dismissed, and the appellants were ordered to pay the respondent's costs. The court's decision reinforced the importance of transparency in business practices and the need for businesses to avoid exploiting the vulnerability of consumers, particularly when it comes to health-related services and products.